Ruth Ann Vleugels, MD, MPH, MBA, provides an overview of oral JAK inhibitors approved for the treatment of atopic dermatitis and describes what makes them an attractive therapeutic option.
Onboarding Patients on JAK Inhibitors for Atopic Dermatitis
An academic dermatologist describes how JAK inhibitors compare with other systemic treatments for atopic dermatitis and provides clinical insights on when to use which treatments.
An expert on atopic dermatitis identifies patients who are good candidates for JAK inhibitors, highlighting contraindications for treatment.
Ruth Ann Vleugels, MD, MPH, MBA, provides insights on factors that inform JAK inhibitor treatment selection for patients with atopic dermatitis.
An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.
An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
The Medical Sisterhood: The Strength Nobody Talks About, with Saakshi Khattri, MD
4
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
5